Efficacy of Flash Glucose-Sensing Technology on the Occurrence of Cardiac Arrhythmias Associated With Hypoglycemia
Efficacy of Flash Continuous Glucose Monitoring (FREESTYLE LIBRE) on the Occurrence of Cardiac Arrhythmias Associated With Hypoglycemia in Patients With Type 2 Diabetes, High Risk of Hypoglycemia and Insulin Therapy : Open-label Randomized Controlled Trial
Hypoglycemia, frequently asymptomatic, may lead to cardiac arrythmias and induce an increased risk of cardiovascular morbidity and mortality in patients with type 2 diabetes (T2D). The study hypothesize is that the hypoglycemia reduction, achieved with the FREESTYLE LIBRE device, a Glucose Continuous Monitoring system, may decrease cardiac arrythmias associated with hypoglycemia. So the main objective is to evaluate the efficacy of the FREESTYLE LIBRE system, associated with a specific therapeutic education on the cardiac arrythmias reduction, compared to a capillary ASG system with standard therapeutic education, in patient with T2D with high risk of hypoglycemia.
This is a open, multicenter, controlled, randomized study in parallel group.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: SAULNIER Pierre-Jean, Prof.
- Phone Number: +33 549444689
- Email: pierre-jean.saulnier@chu-poitiers.fr
Study Contact Backup
- Name: BONNIN Marie, Project chief
- Phone Number: +33 549443317
- Email: Marie.BONNIN@chu-poitiers.fr
Study Locations
-
-
-
Bordeaux, France, 33000
- Recruiting
- University Hospital, Bordeaux
-
Principal Investigator:
- MOHAMMEDI Kamel, Prof.
-
Limoges, France, 87000
- Recruiting
- University Hospital, Limoges
-
Principal Investigator:
- TEISSIER Marie-Pierre, Prof.
-
Nantes, France, 44000
- Recruiting
- University Hospital, Nantes
-
Principal Investigator:
- CARIOU Bertrand, Prof.
-
Niort, France, 79000
- Not yet recruiting
- Hospital, Niort
-
Principal Investigator:
- TEYNIE Julie, Dr.
-
Pau, France, 64000
- Recruiting
- Hospital, Pau
-
Principal Investigator:
- TEYNIE Julie, Dr.
-
Poitiers, France, 86000
- Recruiting
- University Hospital, Poitiers
-
Principal Investigator:
- SAULNIER Pierre-Jean, Prof.
-
Toulouse, France, 31000
- Recruiting
- University Hospital, Toulouse
-
Principal Investigator:
- GOURDY Pierre, Prof.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Type 2 diabetes (diagnosis based on the World Health Organization criteria)
- Treatment with insulin therapy (continuous subcutaneous insulin Infusion or more than 1 daily injection)
- Resting heart beat ≥ 60bpm
High risk of hypoglycemia defined as :
- Estimated glomerular filtration rate 15-59 ml/min/1.73 m² (according to CKD-EPI formula)
- Or history of stable proliferative diabetic retinopathy
- Or body mass index ≤ 30 kg/m²
- Or history of severe hypoglycemia in the previous 6 months
- Or history of non-severe ≤70mg/dL hypoglycemia in the previous 4 weeks
Exclusion criteria:
- Type 1 diabetes mellitus or diabetes due to other cause
- History of atrial fibrillation
- Pacemaker
- Estimated glomerular filtration rate <15 ml/min/1.73 m² (according to CKD-EPI formula)
- Currently using a flash continuous Glucose Monitoring device
- In the investigator's opinion, acute or chronic medical condition considered as unsuitable for inclusion in the study .
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Flash continuous glucose monitoring system
Participants will wear the FREESTYLE LIBRE device and receive a specific therapeutic education for its use.
|
Specific therapeutic education for diabetes self management
|
|
Active Comparator: Standard self monitoring blood glucose system
Participants will use their own usual self monitoring blood glucose system and receive a C They will wear a masked FREESTYLE LIBRE Pro system.
|
Standard therapeutic education for diabetes self management
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Prevalence of cardiac arrythmic events during a 14 days Continuous ECG Monitoring
Time Frame: 14 days
|
Cardiac arrythmic events :
|
14 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Prevalence of each component of the primary outcome
Time Frame: 14 days
|
14 days
|
|
Prevalence of ≥ 5 minutes Atrial Fibrillation episodes
Time Frame: 14 days
|
14 days
|
|
Mean QT interval
Time Frame: First 24 hours
|
First 24 hours
|
|
Prevalence of ventricular extrasystoles
Time Frame: First 24 hours
|
First 24 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SPIDER-STYLE
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.